Physician profile
John D Huber
NPI 1760459069
$11,040.78
in general payments reported to CMS, 2019-2025
32 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 76% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,285 · 2020: $514 · 2021: $1,250 · 2022: $2,048 · 2023: $2,340 · 2024: $1,435 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,871 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,871.49 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,623.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,098.35 | 2019-2025 | |
| Merz North America, INC. | $861.06 | 2019-2021 | |
| Pfizer INC. | $749.72 | 2019-2024 | |
| Janssen Biotech, INC. | $654.31 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $526.63 | 2019-2025 | |
| Lilly USA, LLC | $467.62 | 2019-2025 | Taltz, Ebglyss |
| Incyte Corporation | $429.53 | 2022-2025 | Opzelura |
| Amgen INC. | $415.32 | 2022-2025 | Otezla, Otezla |
| Allergan, INC. | $374.56 | 2019-2021 | |
| Medimetriks Pharmaceuticals, INC. | $354.94 | 2022-2023 | Neo-Synalar |
| Leo Pharma INC. | $338.95 | 2021-2025 | Adbry |
| Ucb, INC. | $260.42 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $259.95 | 2019-2025 | Cabtreo, Jublia, Siliq |
| E.R. Squibb & Sons, L.L.C. | $259.41 | 2022-2025 | Sotyktu |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $249.71 | 2020-2024 | Ilumya, Winlevi, Odomzo |
| Galderma Laboratories, L.P. | $216.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $211.31 | 2022-2024 | Dupixent |
| Almirall LLC | $139.73 | 2022-2023 | Klisyri |
| Arcutis Biotherapeutics, INC. | $120.08 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $115.43 | 2019-2023 | |
| Genentech USA, INC. | $58.11 | 2019-2023 | Xolair |
| Dermavant Sciences, INC. | $55.86 | 2023-2024 | Vtama |
| Journey Medical Corporation | $54.78 | 2019-2023 | |
| Organogenesis INC. | $27.40 | 2023 | Puraply |
| Mylan Pharmaceuticals INC. | $18.75 | 2019 | |
| Biofrontera INC. | $18.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.55 | 2023 | Cyltezo |
| Sanofi-Aventis U.S. LLC | $17.12 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.88 | 2019 | |
| Nabriva Therapeutics, Plc | $15.04 | 2022 | |
| Dermira, INC. | $13.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.